New Therapeutic Approaches to Familial Chylomicronemia Syndrome (FCS)
The understanding of FCS has advanced tremendously over the years, enabling us to find better alternatives in an otherwise undertreated population. The treatment revolves around an extremely low-fat diet, although patients find this difficult to maintain. There are many promising emerging approaches to FCS such as apoC3 inhibitors, ANGPTL3 inhibitors, LPL gene therapy, MTP inhibitors, DGAT inhibitors, apoC2 mimetics, and apoE mimetics. However, due to the rarity of FCS, this effort is slowed by the shortage of these rare study subjects and a regulatory process that at times discourages development in rare disease, which may easily derail such efforts. Several agents remain in development and may never prove useful for FCS, and despite several setbacks we remain hopeful that significant relief is on the way for our FCS patients.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution - Non-Commercial 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in the Medical Student Press Journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).